Trial Profile
A Phase 1 Dose-escalation and Expansion Study of BLZ-100 in Pediatric Subjects With Primary Central Nervous System Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 23 Feb 2023
Price :
$35
*
At a glance
- Drugs Tozuleristide (Primary)
- Indications Brain cancer; CNS cancer
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Blaze Bioscience
- 12 Jun 2018 Planned End Date changed from 1 Feb 2018 to 1 Aug 2018.
- 12 Jun 2018 Planned End Date changed from 1 Feb 2018 to 1 Aug 2018.
- 12 Jun 2018 Planned primary completion date changed from 1 Jan 2018 to 1 Jul 2018.